Venable LLP
On 17 March 2025, Senators Chuck Grassley, John Cornyn, Richard Blumenthal, and Richard Durbin re-introduced “Affordable prescriptions for patients Act” (APPA), which had previously passed through the U.S. Senate in the 2024 Congressional Session, but not by the House. The Committee on Judiciary ordered the Bill to be reported favorably, without amendment, on April 3, 2025. The APPA limits how many patents a reference product sponsor (RPS) can assert against a biosimilar maker in litigations under the Biologics Price, Competition and Innovation Act (BPCIA). SS 271(e).
Please see full publication below for more information.
